Comparative effectiveness of H7N9 vaccines in healthy individuals
Background: Avian H7N9 influenza viruses possess a potential pandemic threat to public health worldwide, and have caused severe infection and high mortality in humans. A series of clinical trials of H7N9 vaccines have been completed. Meta-analyses need to be performed to assess the immunogenicity an...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1515454 |
| _version_ | 1797677426200805376 |
|---|---|
| author | Dan Zheng Feixia Gao Cheng Zhao Yahong Ding Yemin Cao Tianhan Yang Xuesong Xu Ze Chen |
| author_facet | Dan Zheng Feixia Gao Cheng Zhao Yahong Ding Yemin Cao Tianhan Yang Xuesong Xu Ze Chen |
| author_sort | Dan Zheng |
| collection | DOAJ |
| description | Background: Avian H7N9 influenza viruses possess a potential pandemic threat to public health worldwide, and have caused severe infection and high mortality in humans. A series of clinical trials of H7N9 vaccines have been completed. Meta-analyses need to be performed to assess the immunogenicity and safety of H7N9 vaccines. Methods: Database research with defined selection criteria was conducted in PubMed, Cochrane Central Register of Controlled Trials, the World Health Organization’s International Clinical Trials Registry Platform, ClinicalTrials.gov, etc. Data from randomized clinical trials regarding the immunogenicity and safety of H7N9 vaccines were collected and meta-analyzed. Results: For non-adjuvanted H7N9 vaccines, high dose formulations induced limited immunogenicity and increased the risk of local and systemic adverse events, simultaneously. For adjuvanted H7N9 vaccines, on the one hand, ISCOMATRIX, MF59, AS03 and aluminium adjuvants applied in H7N9 vaccines could improve immune responses effectively, and non-aluminium adjuvants had superior performance in saving vaccine dose; on the other hand, aluminium adjuvant had the advantages of safety amongst these adjuvants applied in H7N9 vaccines. Conclusion: H7N9 influenza vaccines with adjuvant might represent the optimal available option in an influenza pandemic, at present. |
| first_indexed | 2024-03-11T22:45:03Z |
| format | Article |
| id | doaj.art-9ea128d56ce34e4ea74ec5c73da3473c |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:45:03Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-9ea128d56ce34e4ea74ec5c73da3473c2023-09-22T08:38:23ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-01-01151809010.1080/21645515.2018.15154541515454Comparative effectiveness of H7N9 vaccines in healthy individualsDan Zheng0Feixia Gao1Cheng Zhao2Yahong Ding3Yemin Cao4Tianhan Yang5Xuesong Xu6Ze Chen7Shanghai Institute of Biological ProductsShanghai Institute of Biological ProductsShanghai University of Traditional Chinese MedicineShanghai Institute of Biological ProductsShanghai University of Traditional Chinese MedicineShanghai Institute of Biological ProductsHuadong Hospital Affiliated to Fudan UniversityShanghai Institute of Biological ProductsBackground: Avian H7N9 influenza viruses possess a potential pandemic threat to public health worldwide, and have caused severe infection and high mortality in humans. A series of clinical trials of H7N9 vaccines have been completed. Meta-analyses need to be performed to assess the immunogenicity and safety of H7N9 vaccines. Methods: Database research with defined selection criteria was conducted in PubMed, Cochrane Central Register of Controlled Trials, the World Health Organization’s International Clinical Trials Registry Platform, ClinicalTrials.gov, etc. Data from randomized clinical trials regarding the immunogenicity and safety of H7N9 vaccines were collected and meta-analyzed. Results: For non-adjuvanted H7N9 vaccines, high dose formulations induced limited immunogenicity and increased the risk of local and systemic adverse events, simultaneously. For adjuvanted H7N9 vaccines, on the one hand, ISCOMATRIX, MF59, AS03 and aluminium adjuvants applied in H7N9 vaccines could improve immune responses effectively, and non-aluminium adjuvants had superior performance in saving vaccine dose; on the other hand, aluminium adjuvant had the advantages of safety amongst these adjuvants applied in H7N9 vaccines. Conclusion: H7N9 influenza vaccines with adjuvant might represent the optimal available option in an influenza pandemic, at present.http://dx.doi.org/10.1080/21645515.2018.1515454h7n9 vaccineadjuvantmeta-analysisimmunogenicitysafety |
| spellingShingle | Dan Zheng Feixia Gao Cheng Zhao Yahong Ding Yemin Cao Tianhan Yang Xuesong Xu Ze Chen Comparative effectiveness of H7N9 vaccines in healthy individuals Human Vaccines & Immunotherapeutics h7n9 vaccine adjuvant meta-analysis immunogenicity safety |
| title | Comparative effectiveness of H7N9 vaccines in healthy individuals |
| title_full | Comparative effectiveness of H7N9 vaccines in healthy individuals |
| title_fullStr | Comparative effectiveness of H7N9 vaccines in healthy individuals |
| title_full_unstemmed | Comparative effectiveness of H7N9 vaccines in healthy individuals |
| title_short | Comparative effectiveness of H7N9 vaccines in healthy individuals |
| title_sort | comparative effectiveness of h7n9 vaccines in healthy individuals |
| topic | h7n9 vaccine adjuvant meta-analysis immunogenicity safety |
| url | http://dx.doi.org/10.1080/21645515.2018.1515454 |
| work_keys_str_mv | AT danzheng comparativeeffectivenessofh7n9vaccinesinhealthyindividuals AT feixiagao comparativeeffectivenessofh7n9vaccinesinhealthyindividuals AT chengzhao comparativeeffectivenessofh7n9vaccinesinhealthyindividuals AT yahongding comparativeeffectivenessofh7n9vaccinesinhealthyindividuals AT yemincao comparativeeffectivenessofh7n9vaccinesinhealthyindividuals AT tianhanyang comparativeeffectivenessofh7n9vaccinesinhealthyindividuals AT xuesongxu comparativeeffectivenessofh7n9vaccinesinhealthyindividuals AT zechen comparativeeffectivenessofh7n9vaccinesinhealthyindividuals |